Deucravacitinib for Juvenile Psoriatic Arthritis
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
- Age
- 5 – 17
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
This trial is looking for children with juvenile psoriatic arthritis who have not had success with previous treatments. Participants will take part in evaluations to help understand the safety and effectiveness of the drug Deucravacitinib.
You may be able to join if
- I have been diagnosed with juvenile psoriatic arthritis.
- I have at least three joints affected by arthritis.
- I have tried at least one type of medicine for juvenile psoriatic arthritis for at least three months without successful results.
You may not be able to join if
- I was diagnosed with juvenile psoriatic arthritis before 5 years old.
- I have other types of juvenile idiopathic arthritis.
- I have a history of chronic eye inflammation or was diagnosed with eye inflammation in the last three months.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Loading trial locations…
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT